Zevra Therapeutics (STU:1GDA) Cyclically Adjusted Book per Share: €-20.36 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1GDA Zevra Therapeutics Inc STU:1GDA
69 GF Score
Price €9.80
GF Value €17.92
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Zevra Therapeutics Cyclically Adjusted Book per Share?

Zevra Therapeutics STU:1GDA +0.82% 69 Cyclically Adjusted Book per Share is €-20.36 as of Jun. 2026. GuruFocus rates STU:1GDA with a GF Score™ of 69/100 and a GF Value™ of €17.92 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Zevra Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was €3.184. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-20.36 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-08-13), Zevra Therapeutics's current stock price is €9.80. Zevra Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €-20.36. Zevra Therapeutics's Cyclically Adjusted PB Ratio of today is .


Zevra Therapeutics  (STU:1GDA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Zevra Therapeutics Cyclically Adjusted Book per Share Related Terms


Zevra Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Zevra Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zevra Therapeutics Cyclically Adjusted Book per Share Chart

Zevra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -22.89 -24.09 -19.02

Zevra Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.41 -20.07 -19.02 -19.85 -20.36

STU:1GDA vs TECX, RLMD, ALT: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Zevra Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zevra Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zevra Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Zevra Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:1GDA
69GF Score
Zevra Therapeutics Inc STU:1GDA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zevra Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zevra Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.184/333.9520*333.9520
=3.184

Current CPI (Jun. 2026) = 333.9520.

Zevra Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 -9.545 241.428 -13.203
201612 -19.370 241.432 -26.793
201703 -34.671 243.801 -47.491
201706 -38.163 244.955 -52.028
201709 -44.057 246.819 -59.610
201712 -53.058 246.524 -71.875
201803 -68.457 249.554 -91.609
201806 -71.947 251.989 -95.349
201809 -81.467 252.439 -107.773
201812 -35.397 251.233 -47.052
201903 -37.867 254.202 -49.747
201906 -40.005 256.143 -52.157
201909 -31.681 256.759 -41.206
201912 -29.494 256.974 -38.329
202003 -17.517 258.115 -22.664
202006 -13.288 257.797 -17.213
202009 -11.676 260.280 -14.981
202012 -12.032 260.474 -15.426
202103 2.485 264.877 3.133
202106 3.101 271.696 3.812
202109 3.171 274.310 3.860
202112 3.214 278.802 3.850
202203 3.205 287.504 3.723
202206 2.722 296.311 3.068
202209 2.746 296.808 3.090
202212 2.053 296.797 2.310
202303 1.968 301.836 2.177
202306 1.864 305.109 2.040
202309 1.746 307.789 1.894
202312 1.366 306.746 1.487
202403 1.073 312.332 1.147
202406 0.719 314.175 0.764
202409 1.181 315.301 1.251
202412 0.706 315.605 0.747
202503 0.694 319.799 0.725
202506 1.845 322.561 1.910
202509 2.018 324.800 2.075
202512 2.323 324.054 2.394
202603 3.011 330.213 3.045
202606 3.184 333.952 3.184

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €-20.36 mean?
Zevra Therapeutics (STU:1GDA) has a Cyclically Adjusted Book per Share of €-20.36 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Zevra Therapeutics and its competitors.
Is Zevra Therapeutics' Cyclically Adjusted Book per Share too high?
Zevra Therapeutics' current Cyclically Adjusted Book per Share is €-20.36. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Cyclically Adjusted Book per Share compare to TECX and RLMD?
Zevra Therapeutics' Cyclically Adjusted Book per Share of €-20.36 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Zevra Therapeutics and its competitors. Zevra Therapeutics's current Cyclically Adjusted Book per Share is €-20.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (STU:1GDA) is currently considered Possible Value Trap. The stock's GF Value™ is €17.92, compared to a current price of €9.80 — trading 45.3% below its estimated fair value. The current Cyclically Adjusted Book per Share is €-20.36. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Zevra Therapeutics (STU:1GDA), the current Cyclically Adjusted Book per Share is €-20.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zevra Therapeutics (STU:1GDA) Overvalued in 2026?

Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued. The current stock price of €9.80 is trading 45.3% below its estimated GF Value™ of €17.92. GuruFocus considers Zevra Therapeutics to be Possible Value Trap.

Key valuation signals for STU:1GDA:

  • Cyclically Adjusted Book per Share: €-20.36
  • GF Value™: €17.92 vs. price of €9.80 (45.3% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the STU:1GDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zevra Therapeutics Business Description

Other Exchanges ZVRA:USA
Address 101 Federal Street, Boston, MA, USA, 02110
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score

Get the complete analysis for STU:1GDA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.80
Price
€17.92
GF Value